NLS Pharmaceutics AG [NASDAQ: NLSP] stock went on an upward path that rose over 107.45% on Friday, amounting to a one-week price increase of more than 156.58%. The company report on March 12, 2021 that NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol).
Agreement provides exclusive rights to all available data included in the original new drug application (“NDA”) for mazindol in the U.S.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has entered into a License Agreement (the “Agreement”) with Novartis Pharma AG, whereby the Company has obtained, on an exclusive basis in the United States, all of the available data referred to and included in the original NDA for Sanorex® (mazindol) submitted to the United States Food and Drug Administration in February 1972. The Agreement encompasses all preclinical and clinical studies, data used for manufacturing including stability and other chemistry manufacturing and controls data, formulation data and know-how for all products containing mazindol as an active substance, and all post-marketing clinical studies and periodic safety reports from 1973 forward.
The market cap for the stock reached $33.29 million, with 5.69 million shares outstanding and 2.87 million shares in the current float. Compared to the average trading volume of 388.16K shares, NLSP stock reached a trading volume of 165942633 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on NLS Pharmaceutics AG [NLSP]:
The Average True Range (ATR) for NLS Pharmaceutics AG is set at 0.72
NLSP Stock Performance Analysis:
NLS Pharmaceutics AG [NLSP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 156.58.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NLSP stock in for the last two-week period is set at 79.02, with the RSI for the last a single of trading hit 84.91, and the three-weeks RSI is set at 74.33 for NLS Pharmaceutics AG [NLSP], while it was recorded at 3.27 for the last single week of trading.
Insight into NLS Pharmaceutics AG Fundamentals:
Reflecting on the efficiency of the workforce at the company, NLS Pharmaceutics AG [NLSP] managed to generate an average of -$1,361,786 per employee.NLS Pharmaceutics AG’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.00 and a Current Ratio set at 0.00.